Magnetic Resonance (MR) Spectroscopy of Breast Cancer Tissue
NCT ID: NCT00184210
Last Updated: 2021-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
1000 participants
OBSERVATIONAL
2000-01-31
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The MR spectral profiles are compared to clinical findings such as the patients diagnosis, lymph node status and tumor size.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Using Magnetic Resonance Spectroscopy With MRI to Non-invasively Determine Breast Cancer Extent of Disease
NCT00312637
Whole-body MRI for the Detection of Metastasis
NCT02183597
Ultra High Field MRI and MRS Techniques in Diagnosing Breast Cancer
NCT01938651
MR Characterisation/Localisation of Breast Cancer
NCT01567137
Magnetic Resonance Breast Tissue Characterisation to Improve Risk Stratification for Breast Cancer
NCT03684733
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Research Council of Norway
OTHER
The Norwegian Women´s Public Health Association
OTHER
Norwegian University of Science and Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tone F Bathen, PhD
Role: STUDY_CHAIR
Norwegian University of Technology and Science
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Norwegian University of Technology and Science
Trondheim, , Norway
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sitter B, Sonnewald U, Spraul M, Fjosne HE, Gribbestad IS. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed. 2002 Aug;15(5):327-37. doi: 10.1002/nbm.775.
Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 2006 Feb;19(1):30-40. doi: 10.1002/nbm.992.
Bathen TF, Jensen LR, Sitter B, Fjosne HE, Halgunset J, Axelson DE, Gribbestad IS, Lundgren S. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status. Breast Cancer Res Treat. 2007 Aug;104(2):181-9. doi: 10.1007/s10549-006-9400-z. Epub 2006 Oct 24.
Sitter B, Bathen TF, Singstad TE, Fjosne HE, Lundgren S, Halgunset J, Gribbestad IS. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed. 2010 May;23(4):424-31. doi: 10.1002/nbm.1478. Epub 2010 Jan 25.
Giskeodegard GF, Grinde MT, Sitter B, Axelson DE, Lundgren S, Fjosne HE, Dahl S, Gribbestad IS, Bathen TF. Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J Proteome Res. 2010 Feb 5;9(2):972-9. doi: 10.1021/pr9008783.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
154080/I30
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.